U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C19H24N2O
Molecular Weight 296.4067
Optical Activity ( + )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMINOPENTAMIDE, (+)-

SMILES

CC(CC(C(N)=O)(C1=CC=CC=C1)C2=CC=CC=C2)N(C)C

InChI

InChIKey=NARHAGIVSFTMIG-UHFFFAOYSA-N
InChI=1S/C19H24N2O/c1-15(21(2)3)14-19(18(20)22,16-10-6-4-7-11-16)17-12-8-5-9-13-17/h4-13,15H,14H2,1-3H3,(H2,20,22)

HIDE SMILES / InChI

Molecular Formula C19H24N2O
Molecular Weight 296.4067
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Aminopentamide is a potent antispasmodic agent. As a cholinergic blocking agent for smooth muscle, its action is similar to atropine. Aminopentamide hydrogen sulfate is marketed under the brand name Centrine indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea of the dogs and cats. Centrine effectively reduces the tone and amplitude of colonic contractions to a greater degree and for a more extended period than does atropine. Centrine effects a reduction in gastric secretion, a decrease in gastric acidity and a marked decrease in gastric motility. Aminopentamide is a nonselective muscarinic cholinergic .

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Centrine

Approved Use

Centrine is indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea.

Launch Date

1970
PubMed

PubMed

TitleDatePubMed
The pharmacological activity of DL-alpha, alpha-diphenyl, gamma-dimethylaminovaleramide (centrine).
1954 Jan
Some aspects of the pharmacology and clinical application of a parasympatholytic agent, aminopentamide.
1956 Sep 1
[Broncholytic effect of a new synthetic drugs: aminopentamide].
1957 Jun
Patents

Sample Use Guides

Dogs and cats: Administer by subcutaneous or intramuscular injection every 8 to 12 hours as follows: For animals weighing up to 10 pounds (lbs): 0.1 mg; For animals weighing 11 to 20 lbs: 0.2 mg; For animals weighing 21 to 50 lbs: 0.3 mg; For animals weighing 51 to 100 lbs: 0.4 mg; For animals weighing over 100 lbs: 0.5 mg. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Following parenteral use, dosage may be continued by oral administration of tablets.
Route of Administration: Other
A concentration of 0.00005 mg of Aminopentamide per ml of bath fluid was found to reduce the frequency of guinea pig ureteral contractions and a concentration of 0.005 mg/ml virtually stopped contractions.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:27:24 GMT 2023
Edited
by admin
on Sat Dec 16 10:27:24 GMT 2023
Record UNII
HI3DVH9WMI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMINOPENTAMIDE, (+)-
Common Name English
BENZENEACETAMIDE, .ALPHA.-(2-(DIMETHYLAMINO)PROPYL)-.ALPHA.-PHENYL-, (+)-
Systematic Name English
VALERAMIDE, 4-(DIMETHYLAMINO)-2,2-DIPHENYL-, (+)-
Systematic Name English
CENTRINE, (+)-
Common Name English
VALERAMIDE-OM, (+)-
Common Name English
DIMEVAMIDE, (+)-
Common Name English
BL-139, (+)-
Code English
Code System Code Type Description
PUBCHEM
22565
Created by admin on Sat Dec 16 10:27:24 GMT 2023 , Edited by admin on Sat Dec 16 10:27:24 GMT 2023
PRIMARY
CAS
5985-88-6
Created by admin on Sat Dec 16 10:27:24 GMT 2023 , Edited by admin on Sat Dec 16 10:27:24 GMT 2023
PRIMARY
FDA UNII
HI3DVH9WMI
Created by admin on Sat Dec 16 10:27:24 GMT 2023 , Edited by admin on Sat Dec 16 10:27:24 GMT 2023
PRIMARY